Tyrosols and derivatives
Medchemexpress LLC 6-(N-carbamoyl-2,6-difluoroanilino)-2-(2,4-difluorophenyl)pyridine-3-carboxamide | 745833-23-2 | MFCD11616590 | 99.7% | 404.32 g/mol | C19H12F4N4O2 | 100 MG
VX-702 is a small-molecule research inhibitor selective for the p38α isoform of mitogen-activated protein kinase (MAPK). It is used to probe MAPK signaling and inflammatory cytokine production in preclinical and cellular studies. The compound is supplied as a powder with high reported purity and documented potency against p38α.
Apexbio Technology LLC VX-702 479543-46-9; 745833-23-2 10mM (in 1mL DMSO)
VX-702 is a small-molecule inhibitor targeting p38 mitogen-activated protein kinase (MAPK) also known as MAPK14 It is designed to inhibit p38 MAPK thereby regulating cellular responses to cytokine signaling and various stressors VX-702 exerts its biological activity primarily through ATP-competitive inhibition In experimental models VX-702 demonstrates potent inhibition with reported IC50 values ranging from 4 to 20 nM Based on these pharmacological properties VX-702 holds research potential in the study of p38 MAPK-dependent pathways platelet storage lesions and renal excretion mechanisms
Apexbio Technology LLC VX-702 479543-46-9; 745833-23-2 25mg
VX-702 is a small-molecule inhibitor targeting p38 mitogen-activated protein kinase (MAPK) also known as MAPK14 It is designed to inhibit p38 MAPK thereby regulating cellular responses to cytokine signaling and various stressors VX-702 exerts its biological activity primarily through ATP-competitive inhibition In experimental models VX-702 demonstrates potent inhibition with reported IC50 values ranging from 4 to 20 nM Based on these pharmacological properties VX-702 holds research potential in the study of p38 MAPK-dependent pathways platelet storage lesions and renal excretion mechanisms